Comparison of proteomic strategies to identify antibodies resulting from the humoral immune response to cancer;Étude de la réaction immunitaire humorale aux cancers par des approches protéomiques

Medecine/Sciences

Volumn 24, Issue 12, 2008, Pages 1071-1076

  Desmetz, Caroline ^a   Mangé, Alain ^a   Solassol, Jérôme ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CANCER ANTIBODY; COMPLEMENTARY DNA; TUMOR ANTIGEN;

BACTERIOPHAGE LAMBDA; BIOSYNTHESIS; BLOOD; COMPARATIVE STUDY; DNA PROBE; DNA SEQUENCE; ESCHERICHIA COLI; GENE LIBRARY; GENETICS; HUMAN; IMAGE SUBTRACTION; IMMUNOLOGY; ISOELECTRIC FOCUSING; ISOLATION AND PURIFICATION; METHODOLOGY; MOLECULAR CLONING; NEOPLASM; PROTEOMICS; REVIEW; SILVER STAINING; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; BACTERIOPHAGE LAMBDA; CLONING, MOLECULAR; DNA PROBES; DNA, COMPLEMENTARY; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; ESCHERICHIA COLI; GENE LIBRARY; HUMANS; ISOELECTRIC FOCUSING; NEOPLASMS; PROTEOMICS; SEQUENCE ANALYSIS, DNA; SILVER STAINING; SUBTRACTION TECHNIQUE;

EID: 58449117721     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/200824121071     Document Type: Review

References (41)

1. Baldwin RW. Tumour-specific immunity against spontaneous rat tumours. Int J Cancer 1966 ; 1 : 257-64.
2. Baldwin RW. An immunological approach to cancer. Lav Ist Anat Istol Patol Univ Studi Perugia 1968 ; 28 : 65-85.
3. Baldwin RW. Tumour-associated antigens and tumour-host interactions. Proc R Soc Med 1971 ; 64 : 1039-42.
4. Machour N, Gilbert D, Vittecoq O, et al. Protéomique et autoanticorps. Med Sci (Paris) 2005 ; 21 : 759-64.
5. Anderson KS, LaBaer J. The sentinel within: exploiting the immune system for cancer biomarkers. J Proteome Res 2005 ; 4 : 1123-33.
6. Sahin U, Tureci O, Schmitt H, et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Nal Acad Sci USA 1995 ; 92 : 11810-3.
7. Chen YT, Scanlan MJ, Sahin U, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 1997 ; 94 : 1914-8.
8. Tureci O, Mack U, Luxemburger U, et al. Humoral immune responses of lung cancer patients against tumor antigen NY-ESO-1. Cancer Lett 2006 ; 236 : 64-71.
9. Fossa A, Berner A, Fossa SD, et al. NY-ESO-1 protein expression and humoral immune responses in prostate cancer. Prostate 2004 ; 59 : 440-7.
10. Maio M, Coral S, Sigalotti L, et al. Analysis of cancer/testis antigens in sporadic medullary thyroid carcinoma: expression and humoral response to NY-ESO-1. J Clin Endocrinol Metab 2003 ; 88 : 748-54.
11. Stockert E, Jager E, Chen YT, et al. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 1998 ; 187 : 1349-54.
12. Park S, Lim Y, Lee D, et al. Identification and characterization of a novel cancer/testis antigen gene CAGE-1. Biochim Biophys Acta 2003 ; 1625 : 173-82.
13. Jager D, Stockert E, Gure AO, et al. Identification of a tissue-specific putative transcription factor in breast tissue by serological screening of a breast cancer library. Cancer Res 2001 ; 61 : 2055-61.
14. + T-cell immune response. Int J Cancer 2004 ; 109 : 909-18.
15. Pallasch CP, Struss AK, Munnia A, et al., Autoantibodies against GLEA2 and PHF3 in glioblastoma: tumor-associated autoantibodies correlated with prolonged survival. Int J Cancer 2005 ; 117 : 456-9.
16. Prasannan L, Misek DE, Hinderer R, et al., Identification of beta-tubulm isoforms as tumor antigens in neuroblastoma. Clin Cancer Res 2000 ; 6 : 3949-56.
17. Brichory FM, Misek DE, Yim AM, et al. An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer. Proc Natl Acad Sci USA 2001 ; 98 : 9824-9.
18. Klade CS, Voss T, Krystek E, et al. Identification of tumor antigens in renal cell carcinoma by serological proteome analysis. Proteomics 2001 ; 1 : 890-8.
19. Lichtenfels R, Kellner R, Atkins D, et al., Identification of metabolic enzymes in renal cell carcinoma utilizing PROTEOMEX analyses. Biochim Biophys Acta 2003 ; 1646 : 21-31.
20. Lichtenfels R, Kellner R, Bukur J, et al. Heat shock protein expression and anti-heat shock protein reactivity in renal cell carcinoma. Proteomics 2002 ; 2 : 561-70.
21. Unwin RD, Harnden P, Pappin D, et al. Serological and proteomic evaluation of antibody responses in the identification of tumor antigens in renal cell carcinoma. Proteomics 2003 ; 3 : 45-55.
22. Fujita Y, Nakanishi T, Hiramatsu M, et al. Proteomics-based approach identifying autoantibody against peroxiredoxin VI as a novel serum marker in esophageal squamous cell carcinoma. Clin Cancer Res 2006 ; 12 : 6415-20.
23. Yang F, Xiao ZQ, Zhang XZ, et al., Identification of tumor antigens in human lung squamous carcinoma by serological proteome analysis. J Proteome Res 2007 ; 6 : 751-8.
24. Le Naour F, Brichory F, Misek DE, et al. A distinct repertoire of autoantibodies in hepatocellular carcinoma identified by proteomic analysis. Mol Cell Proteomics 2002 ; 1 : 197-203.
25. Hong SH, Misek DE, Wang H, et al. An autoantibody-mediated immune response to calreticulin isoforms in pancreatic cancer. Cancer Res 2004 ; 64 : 5504-10.
26. Le Naour F, Misek DE, Krause MC, et al. Proteomics-based identification of RS/DJ-1 as a novel circulating tumor antigen in breast cancer. Clin Cancer Res 2001 ; 7 : 3328-35.
27. Hanash S. Harnessing immunity for cancer marker discovery. Nat Biotechnol 2003 ; 21 : 37-8.
28. Marouga R, David S, Hawkins E. The development of the DIGE system: 2D fluorescence difference gel analysis technology. Anal Bioanal Chem 2005 ; 382 : 669-78.
29. Gagnon A, Kim JH, Schorge JO, et al. Use of a combination of approaches to identify and validate relevant tumor-associated antigens and their corresponding autoantibodies in ovarian cancer patients. Clin Cancer Res 2008 ; 14 : 764-71.
30. Feng Y, Ke X, Ma R, et al. Parallel detection of autoantibodies with microarrays in rheumatoid diseases. Clin Chem 2004 ; 50 : 416-22.
31. Mattoon D, Michaud G, Merkel J, et al. Biomarker discovery using protein microarray technology platforms: antibody-antigen complex profiling. Expert Rev Proteomics 2005 ; 2 : 879-89.
32. Ehrlich JR, Qin S, Liu BC. The reverse capture autoantibody microarray: a native antigen-based platform for autoantibody profiling. Nat Protoc 2006 ; 1 : 452-60.
33. Miller JC, Zhou H, Kwekel J, et al. Antibody microarray profiling of human prostate cancer sera: antibody screening and identification of potential biomarkers. Proteomics 2003 ; 3 : 56-63.
34. Wang X, Yu J, Sreekumar A, et al. Autoantibody signatures in prostate cancer. N Engl J Med 2005 ; 353 : 1224-35.
35. Qiu J, Madoz-Gurpide J, Misek DE, et al. Development of natural protein microarrays for diagnosing cancer based on an antibody response to tumor antigens. J Proteome Res 2004 ; 3 : 261-7.
36. Nam MJ, Madoz-Gurpide J, Wang H, et al. Molecular profiling of the immune response in colon cancer using protein microarrays: occurrence of autoantibodies to ubiquitin C-terminal hydrolase L3. Proteomics 2003 ; 3 : 2108-15.
37. Chapman C, Murray A, Chakrabarti J, et al. Autoantibodies in breast cancer: their use as an aid to early diagnosis. Ann Oncol 2007 ; 18 : 868-73.
38. Koziol JA, Zhang JY, Castano CA, et al. Recursive partitioning as an approach to selection of immune markers for tumor diagnosis. Clin Cancer Res 2003 ; 9 : 5120-6.
39. Zhong L, Peng X, Hidalgo GE, et al. Identification of circulating antibodies to tumor-associated proteins for combined use as markers of non-small cell lung cancer. Proteomics 2004 ; 4 : 1216-25.
40. Lucchi G, Hendra JB, Pecqueur D, Ducoroy P. Vers une standardisation des outils pour les études de protéomique clinique. Med Sci (Paris) 2007 ; 23(suppl 1) : 19-22.
41. Solary E. Protéomique clinique en oncologie. Med Sci (Paris) 2007 ; 23 (suppl 1) : 3-4.